Preview

Современная ревматология

Расширенный поиск

Коморбидные инфекции у больных ревматоидным артритом: Status praesens

https://doi.org/10.14412/1996-7012-2019-3-102-108

Полный текст:

Аннотация

В современной ревматологии проблема коморбидных инфекций (КИ) сохраняет свою актуальность. Это обусловлено как наличием аутоиммунного ревматического заболевания, так и необходимостью применения препаратов с имммуносупрессивным действием. В статье освещены современные аспекты основных КИ (туберкулез, пневмонии, хронические вирусные инфекции) у больных ревматоидным артритом (РА). Показано значение превентивных мероприятий в отношении КИ при лечении РА. Подчеркнуто значение иммунизации (в первую очередь гриппозными и пневмококковыми вакцинами) больных РА с целью снижения частоты инфекций нижних дыхательных путей и риска летальных исходов от них.

Об авторах

Б. С. Белов
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия

Белов Борис Сергеевич.

115522, Москва, Каширское шоссе, 34А.



Г. М. Тарасова
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия

115522, Москва, Каширское шоссе, 34А.



Д. В. Буханова
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия

115522, Москва, Каширское шоссе, 34А.



Литература

1. Wolfe F, Mitchell DM, Sibley JT. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994 Apr;37(4):481-94.

2. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls. Arthritis Rheum. 2002 Sep;46(9):2287-93.

3. Белов БС, Балабанова РМ, Манукян СГ и др. Коморбидные инфекции при ревматических заболеваниях. Тезисы докладов международной конференции ревматологов. Чимкент; 2006. С. 17.

4. Буханова ДВ, Белов БС, Тарасова ГМ и др. Коморбидные инфекции при ревматических заболеваниях (по данным ФГБНУ НИИР им. В.А. Насоновой). Медицинский совет. 2019;(9):80-3.

5. Aydin V, Akici A, Isli F, et al. Relative risk of tuberculosis in patients with rheumatic diseases managed with antitumour necrosis factor-alpha therapy: A nationwide cohort study. J Clin Pharm Ther. 2019 Feb 14. doi: 10.1111/jcpt.12814. [Epub ahead of print]

6. Liu YJ, Xu J, Guo Q, et al. The prevalence of latent tuberculosis infection in patients with inflammatory arthritis and the diagnostic efficacy of different screening methods. Zhonghua YiXue Za Zhi. 2019 Jan 1;99(1): 20-24. doi: 10.3760/cma.j.issn.0376-2491.2019.01.005.

7. Лукина ГВ, Борисов СЕ. Скрининг и мониторинг туберкулезной инфекции у больных ревматическими заболеваниями, получающих генно-инженерные биологические препараты. В кн.: Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. С. 394-410.

8. Yun H, Xie F, Delzell E, et al. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Arthritis Rheumatol. 2016 Jan;68(1):56-66. doi: 10.1002/art.39399.

9. Yazici Y, Curtis JR, Ince A, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012 Feb;71(2):198-205. doi: 10.1136/ard.2010.148700

10. Rodriguez-Garcia SC, Castellanos-Moreira R, Hernandez V, et al. Coverage, predictors of vaccination and frequency of severe infections due to streptococcus pneumoniae in a cohort of patients with chronic inflammatory arthritis within an eighteen-year period . Ann Rheum Dis. 2019;78 (Suppl 2) 638. doi: 10.1136/annrheumdis-2019-eular.2183

11. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006 Feb;54(2): 628-34. DOI:10.1002/art.21568

12. Полянская МВ. Пневмония у пациентов с ревматическими заболеваниями: частота встречаемости, клиническая картина, факторы риска. Автореф. дис.... канд. мед. наук. Москва; 2009. 24 с.

13. Zamora-Legoff JA, Krause ML, Crowson CS. Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2016 Oct;35(10):2585-9. doi: 10.1007/s10067-016-3357-z. Epub 2016 Jul 22.

14. Duarte AC, Porter JC, Leandro MJ, et al. The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment. Rheumatology (Oxford). 2019 May 14. pii: kez177. doi: 10.1093/rheumatology/kez177. [Epub ahead of print]

15. Singh N, Varghese J, England BR, et al. Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis. Semin Arthritis Rheum. 2019 May 15. pii: S0049-0172(18)30639-5. doi: 10.1016/j.semarthrit.2019.04.005. [Epub ahead of print]

16. Lamb YN, Deeks ED. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis. Drugs. 2018 Jun;78(9):929-940. doi: 10.1007/s40265-018-0929-z

17. Smolen JS, Genovese MC, Takeuchi T, et al. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361

18. Stamp LK, Hurst M. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol. 2010 Apr;37(4):686-8. doi: 10.3899/jrheum. 091426.

19. Grubbs JA, Baddley JW. Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis. Curr Rheumatol Rep. 2014 Oct;16(10):445. doi: 10.1007/s11926-014-0445-4.

20. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010 Feb;69(2):380-6. doi: 10.1136/ard.2008.089276

21. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011 Apr;70(4):616-23. doi: 10.1136/ard.2010.137422. Epub 2010 Dec 21.

22. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety pro-file of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008 Feb;67(2):189-94. Epub 2007 Jul 20.

23. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009 May;36(5):898-906. doi: 10.3899/jrheum.080791. Epub 2009 Mar 30.

24. Komano Y, Tanaka M, Nanki T, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

25. Beukelman T, Xie F, Baddley JW, et al. Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum. 2013 May;65(5):1384-9. doi: 10.1002/art.37866.

26. Mori S, Sugimoto M. Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations. Clin Med Insights Circ RespirPulm Med. 2015 Sep 6;9(Suppl 1): 29-40. doi: 10.4137/CCRPM.S23286. eCollection 2015.

27. Louie GH, Wang Z, Ward MM. Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996-2007. Arthritis Rheum. 2010 Dec;62(12):3826-7. doi: 10.1002/art.27735.

28. Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis. 2014 Jun;58(12): 1649-57. doi: 10.1093/cid/ciu185. Epub 2014 Mar 18.

29. Foocharoen C, Siriphannon Y, Mahakkanukrauh A, et al. Incidence rate and causes of infection in Thai systemic sclerosis patients. Int J Rheum Dis. 2012 Jun;15(3): 277-83. doi: 10.1111/j.1756-185X.2012.01728.x. Epub 2012 May 20.

30. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22;354(25):2655-66.

31. Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis. 2014 Nov;73(11):1942-8. doi: 10.1136/annrheumdis-2013-203407

32. Galli M, Antinori S, Atzeni F, et al. Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017 Nov-Dec;35(6):1018-1028.

33. Perez-Sola MJ, Torre-Cisneros J, Perez-Zafrilla B, et al. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc). 2011 Nov 12;137(12):533-40. doi: 10.1016/j.medcli.2010.11.032.

34. Белов БС, Тарасова ГМ, Буханова ДВ. Микотические инфекции в ревматологии. Современная ревматология. 2017;11(2):18-24. doi: 10.14412/1996-7012-2017-2-18-24

35. Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/antihepatitis B core antigen positive) with rheu-matic diseases. Arthritis Care Res (Hoboken). 2010 Jun;62(6):749-54. doi: 10.1002/acr.20130.

36. Mok CC, Ho LY, Chan KL, et al. Prevalence of occult hepatitis b carrier status and its associated factors in patients with rheumatic diseases undergoing biological therapies. Ann Rheum Dis. Jun 2018;77 (Suppl 2):317. doi: 10.1136/annrheumdis-2018-eular.4333

37. Arevalo Ruales K, Soler Bas B, Ivorra Cortes J, et al. Prevalence of hepatitis b and c infection and reactivation in patients receiving biologic iv therapies. Ann Rheum Dis. Jun 2017; 76 (Suppl 2):1039. doi: 10.1136/annrheumdis-2017-eular.4827

38. Chen YM, Huang WN, Wu YD et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018 May;77(5):780-782. doi: 10.1136/annrheumdis-2017-211322. Epub 2017 Jun 29.

39. Mahroum N, Watad A, Tiosano S, et al. Chronic hepatitis B viral infection among RA patients-a cross-sectional control study. Clin Rheumatol. 2019 May;38(5):1237-1241. doi: 10.1007/s10067-019-04448-x. Epub 2019 Feb 8.

40. Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012 Aug;31(8):1169-75. doi: 10.1007/s10067-012-1988-2. Epub 2012 Apr 28.

41. Chen MH, Chen MH, Liu CY, et al. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment. J Infect Dis. 2017 Feb 15;215(4): 566-573. doi: 10.1093/infdis/jiw606.

42. Chen YM, Yang SS, Chen DY. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. J Microbiol Immunol Infect. 2019 Feb;52(1):1-8. doi: 10.1016/j.jmii.2017.10.002/

43. Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii2-34. doi: 10.1136/annrheumdis-2013-203348.

44. Chen YM, Chen HH, Huang WN, et al. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. Int J Rheum Dis. 2019 Jun;22(6):1145-1151. doi: 10.1111/1756-185X.13582. Epub 2019 May 22.

45. Sebastiani M, Milazzo L, Atzeni F, et al. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. Mod Rheumatol. 2019 Jan 22:1-8. doi: 10.1080/14397595.2018.1558918. [Epub ahead of print]

46. Inanc N, Direskeneli H. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int. 2006 Nov;27(1):67-71. Epub 2006 Aug 2. doi:10.1007/s00296-006-0165-9

47. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009 May 15;48(10):1364-71. doi: 10.1086/598331.

48. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.

49. Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014 May; 81(3):215-21. doi: 10.1016/j.jbspin.2013.07.009.

50. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Oct;66(10):2675-84. doi: 10.1002/art.38745.

51. Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019 Apr 5; 21(1):89. doi: 10.1186/s13075-019-1866-2.

52. Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019 Apr 14. pii: kez087. doi: 10.1093/rheumatology/kez087. [Epub ahead of print]

53. Atzeni F, Talotta R, Nucera V, et al. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Rev Clin Immunol. 2018 Nov; 14(11):945-956. doi: 10.1080/1744666X.2018.1504678. Epub 2018 Aug 21.

54. Almanzar G, Kienle F, Schmalzing M, et al. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019 May 18. pii: kez175. doi: 10.1093/rheumatology/kez175. [Epub ahead of print]

55. Bukhanova D, Belov B, Tarasova G, et al. Assessment of efficacy, safety and immunogenicity of a trivalent split-virus influenza vaccine in patients with rheumatic diseases. Ann Rheum Dis. 2019;78 (Suppl 2):676. doi: 10.1136/annrheumdis-2019-eular.3663

56. Bukhanova D, Belov B, Tarasova G, et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results from 5-year follow up. Ann Rheum Dis. 2019;78 (Suppl 2): 336. doi: 10.1136/annrheumdis-2019-eular.3173


Для цитирования:


Белов Б.С., Тарасова Г.М., Буханова Д.В. Коморбидные инфекции у больных ревматоидным артритом: Status praesens. Современная ревматология. 2019;13(3):102-108. https://doi.org/10.14412/1996-7012-2019-3-102-108

For citation:


Belov B.S., Tarasova G.M., Bukhanova D.V. Infectious comorbidities in patients with rheumatoid arthritis: Status praesens. Modern Rheumatology Journal. 2019;13(3):102-108. (In Russ.) https://doi.org/10.14412/1996-7012-2019-3-102-108

Просмотров: 26


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)